Search results
Results from the WOW.Com Content Network
Synthetic cannabinoids were made for cannabinoid research focusing on tetrahydrocannabinol (THC), cannabinoid receptors, and the endocannabinoids that activate them in the body. Synthetic cannabinoids were needed partly due to legal restrictions on natural cannabinoids, which make them difficult to obtain for research.
On the evening of April 15, the three sought to buy K2 synthetic marijuana, and chose to break into the Cipriano household as Cipriano knew there were debit cards in the car in the garage. To this end, Young drove the men to the house, and waited in his truck nearby while Zinderman boosted Cipriano as he entered the garage side window.
Synthetic marijuana, commonly called "K2" or "spice," is especially popular in prison systems and jails across the country because it's cheap, easy to smuggle, and doesn't show up in routine urine ...
John W. Huffman. John William Huffman (July 21, 1932 – May 14, 2022) was a professor of organic chemistry at Clemson University who first synthesised novel cannabinoids. [1] His research, funded by the National Institute on Drug Abuse, was focused on making a drug to target endocannabinoid receptors in the body. [2][3]
The AP said it paid for the analysis of 30 vapes, and 10 of them had synthetic marijuana, known as K2 or Spice. Report: Synthetic Marijuana, Fentanyl Found In CBD-Labeled Products Skip to main content
The man who drove his car into a crowded sidewalk in Times Square on Thursday was high on synthetic marijuana, known on the street as K2, according to ABC News.. Richard Rojas, 26, plowed down ...
When synthetic cannabinoids are used recreationally, they present significant health dangers to users. [100] In the period of 2012 through 2014, over 10,000 contacts to poison control centers in the United States were related to use of synthetic cannabinoids. [100] Medications containing natural or synthetic cannabinoids or cannabinoid analogs:
AB-FUBINACA (AMB-FUBINACA[2]) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB 1 and 23.2 nM at CB 2 and EC 50 values of 1.8 nM at CB 1 and 3.2 nM at CB 2. [3][4][5] It was originally developed by Pfizer in 2009 as an analgesic medication [6] but was never pursued for human use.